Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777407 | 1.00 | CTSL (0.47) | CTSLCTSBCTSSCYP2D6ALDH1A1 | |
| SCHEMBL28571926 | 0.90 | CTSB (0.47) | CTSLCTSBCTSSCYP2D6ALDH1A1 | |
| SCHEMBL28571925 | 0.90 | CTSB (0.47) | CTSLCTSBCTSSCYP2D6ALDH1A1 | |
| SCHEMBL25199383 | 0.84 | CTSS (0.51) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL25199386 | 0.84 | CTSS (0.51) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL22961966 | 0.83 | NPFFR1 (0.53) | CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL23120819 | 0.83 | NPFFR1 (0.53) | CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL25265162 | 0.82 | CTSL (0.44) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL25188402 | 0.82 | CTSL (0.44) | CTSLCTSBCTSSLMNASMN1; SMN2 | |
| SCHEMBL143763 | 0.81 | CTSS (0.57) | CTSLCTSBCTSSALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | CTSL 3195/4885CTSB 2435/4885CTSS 3338/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | CTSL 3195/4885CTSB 2435/4885CTSS 3338/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | CTSL 3195/4885CTSB 2435/4885CTSS 3338/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | CTSL 3195/4885CTSB 2435/4885CTSS 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.